BMO
AZN icon

Beck Mack & Oliver’s AstraZeneca AZN Stock Holding History

Beck Mack & Oliver’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,357
Closed -$211K – 191
2024
Q3 		$211K Hold
1,357
– – ﹤0.01% 163
2024
Q2 		$212K Buy
+1,357
New +$204K ﹤0.01% 166
2024
Q1 		– Sell
-1,732
Closed -$233K – 177
2023
Q4 		$233K Hold
1,732
– – 0.01% 162
2023
Q3 		$235K Buy
+1,732
New +$237K 0.01% 150

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Beck Mack & Oliver's AZN Position: Q4 2024 in Review

Beck Mack & Oliver sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 1,357 shares — an estimated $211K sold.

Beck Mack & Oliver first reported a position in AZN in Q3 2023 and held it in 4 quarters. The position peaked at $235K in Q3 2023. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

  • Beck Mack & Oliver reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
  • Beck Mack & Oliver sold 1,357 AstraZeneca shares in Q4 2024, an estimated $211K.
  • Beck Mack & Oliver first reported a position in AstraZeneca in Q3 2023 and held it in 4 quarters.
  • Beck Mack & Oliver's AstraZeneca position peaked at $235K in Q3 2023.
  • 1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on Beck Mack & Oliver's 13F filing for Q4 2024, filed 13 Feb 2025.